Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Free Cash Flow: 2022-2025

Historic Free Cash Flow for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -$2.5 million.

  • bioAffinity Technologies' Free Cash Flow fell 44.11% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.5 million, marking a year-over-year decrease of 17.02%. This contributed to the annual value of -$7.3 million for FY2024, which is 21.17% down from last year.
  • Per bioAffinity Technologies' latest filing, its Free Cash Flow stood at -$2.5 million for Q3 2025, which was up 6.91% from -$2.7 million recorded in Q2 2025.
  • bioAffinity Technologies' Free Cash Flow's 5-year high stood at -$376,141 during Q2 2022, with a 5-year trough of -$2.7 million in Q2 2025.
  • For the 3-year period, bioAffinity Technologies' Free Cash Flow averaged around -$1.8 million, with its median value being -$1.7 million (2024).
  • Its Free Cash Flow has fluctuated over the past 5 years, first slumped by 262.58% in 2023, then rose by 29.10% in 2025.
  • Quarterly analysis of 4 years shows bioAffinity Technologies' Free Cash Flow stood at -$1.3 million in 2022, then dropped by 23.24% to -$1.6 million in 2023, then decreased by 4.64% to -$1.7 million in 2024, then crashed by 44.11% to -$2.5 million in 2025.
  • Its Free Cash Flow was -$2.5 million in Q3 2025, compared to -$2.7 million in Q2 2025 and -$1.7 million in Q1 2025.